Entrada Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 7, 2024
TRDA$4.69-4.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $68,436 | $67,602 |
| Marketable securities | 258,978 | 284,367 |
| Collaboration receivable | 77,514 | 5,878 |
| Prepaid expenses and other current assets | 9,244 | 11,924 |
| Total current assets | 414,172 | 369,771 |
| Property and equipment, net | 11,002 | 11,191 |
| Restricted cash | 3,950 | 3,950 |
| Right-of-use assets, operating leases | 78,958 | 81,490 |
| Other non-current assets | 2,762 | 2,790 |
| Total assets | $510,844 | $469,192 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $2,527 | $3,277 |
| Accrued expenses and other current liabilities | 8,792 | 11,325 |
| Income taxes payable | 5,855 | 4,024 |
| Operating lease obligations, current portion | 8,301 | 7,909 |
| Deferred revenue, current portion | 148,463 | 132,261 |
| Total current liabilities | 173,938 | 158,796 |
| Operating lease obligations, net of current portion | 58,131 | 60,321 |
| Deferred revenue, net of current portion | 9,408 | 7,715 |
| Total liabilities | 241,477 | 226,832 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Common stock, par value $0.0001; 150,000,000 shares authorized; 33,625,117 shares issued and 33,604,053 shares outstanding as of March 31, 2024 and 33,461,771 shares issued and 33,437,296 shares outstanding as of December 31, 2023 | 3 | 3 |
| Additional paid‑in capital | 441,084 | 437,132 |
| Accumulated other comprehensive (loss) income | (246) | 195 |
| Accumulated deficit | (171,474) | (194,970) |
| Total stockholders’ equity | 269,367 | 242,360 |
| Total liabilities and stockholders’ equity | $510,844 | $469,192 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.